- Home
- VTYX vs MRCC Comparison
VTYX vs MRCC Comparison
Compare VTYX & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- MRCC
- Stock Information
- Founded
- VTYX 2018
- MRCC 2011
- Country
- VTYX United States
- MRCC United States
- Employees
- VTYX N/A
- MRCC N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- MRCC Investment Managers
- Sector
- VTYX Health Care
- MRCC Finance
- Exchange
- VTYX Nasdaq
- MRCC Nasdaq
- Market Cap
- VTYX 154.9M
- MRCC 155.1M
- IPO Year
- VTYX 2021
- MRCC 2012
- Fundamental
- Price
- VTYX $2.30
- MRCC $7.60
- Analyst Decision
- VTYX Buy
- MRCC Hold
- Analyst Count
- VTYX 2
- MRCC 1
- Target Price
- VTYX $9.00
- MRCC $8.00
- AVG Volume (30 Days)
- VTYX 441.6K
- MRCC 71.0K
- Earning Date
- VTYX 11-06-2025
- MRCC 11-11-2025
- Dividend Yield
- VTYX N/A
- MRCC 13.16%
- EPS Growth
- VTYX N/A
- MRCC N/A
- EPS
- VTYX N/A
- MRCC 0.09
- Revenue
- VTYX N/A
- MRCC $51,229,000.00
- Revenue This Year
- VTYX N/A
- MRCC N/A
- Revenue Next Year
- VTYX N/A
- MRCC N/A
- P/E Ratio
- VTYX N/A
- MRCC $86.03
- Revenue Growth
- VTYX N/A
- MRCC N/A
- 52 Week Low
- VTYX $0.78
- MRCC $5.96
- 52 Week High
- VTYX $3.39
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- VTYX 39.52
- MRCC 75.84
- Support Level
- VTYX $2.31
- MRCC $7.43
- Resistance Level
- VTYX $2.54
- MRCC $7.66
- Average True Range (ATR)
- VTYX 0.14
- MRCC 0.13
- MACD
- VTYX -0.02
- MRCC -0.01
- Stochastic Oscillator
- VTYX 0.00
- MRCC 89.29
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.